Mai Capital Management Reneo Pharmaceuticals, Inc. Transaction History

Mai Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$5.44 - $8.13 $311,347 - $465,304	57,233 Added 86.08%	123,720 $942,000
Q2 2023 Aug 02, 2023	BUY	$5.44 - $10.5 $71,040 - $137,119	13,059 Added 24.44%	66,487 $436,000
Q1 2023 May 10, 2023	BUY	$2.44 - $6.42 $63,918 - $168,178	26,196 Added 96.2%	53,428 $319,000
Q4 2022 Feb 09, 2023	SELL	$1.8 - $3.52 $64,760 - $126,642	-35,978 Reduced 56.92%	27,232 $63,000
Q3 2022 Nov 15, 2022	BUY	$2.35 - $4.85 $148,543 - $306,568	63,210 New	63,210 $212,000

31M

50.8K

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.